阿魏酸钠预防对比剂对肾脏损害的研究  

The Sodium Ferulate Contrast Agents Prevention of Kidney Damage

作　　者：董彦文[1] 王凯[1] 牧骑[1] 祁宏[1] 安静[1] 姚树青 

机构地区：[1]赤峰学院附属医院心内科,内蒙古赤峰024000 [2]河北省康保县中医院,河北康保076650

出　　处：《内蒙古医学杂志》2013年第2期179-181,共3页Inner Mongolia Medical Journal

摘　　要：目的:研究阿魏酸钠预防对比剂对肾脏的损害。方法:将126例行冠状动脉介入治疗的患者随机分对照组和治疗组,治疗组术前24 h及术后予阿魏酸钠300 mg每日1次静点。观察术前、术后血清肌酐(Scr),内生肌酐清除率(Ccr),尿β2微球蛋白变化的情况。结果:内生肌酐清除率(Ccr)术后1、2 d时,治疗组显著高于对照组(P<0.05),尿β2微球蛋白术后1、2 d时治疗组显著低于对照组(P<0.05)。结论:阿魏酸钠可以用来预防对比剂对肾脏的损害。Objective：To study if the sodium ferulate will prevent kidney damage induced by contrast agents. Methods： 126 patients, who were operated with coronary intervention, were divided into control group and treatment group. In treatment group, sodium ferulate was injected intravenously 300 mg once daily before 24 and after surgery. Before and after surgery, the levels of serum ereatinine （Scr）, endogenous creatinine clear- anee rate （Cer）, urine 13z microglobulin were compared. Results：The level of endogenous creatinine clearance rate （Ccr） in the treatment group was higher than in the control group（ P 〈 0.05）. The level of urine 13z microglobulin in the treatment group was lower than in the control group（P 〈 0.05）. Conclusion： Sodium ferulate can be used to prevent kidney damage induced by contrast agents.

关 键 词：阿魏酸钠 对比剂 肾损害 

分 类 号：R334.1[医药卫生—人体生理学]